









Markets
/
Stocks
/
nasdaq-cycn
/

Cyclerion Therapeutics Inc

CYCN

2.380USD

+0.040+1.71%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

7.32MMarket Cap

LossP/E TTM



Cyclerion Therapeutics Inc

2.380

+0.040+1.71%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

255 / 506

Overall Ranking

414 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 573.40% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.00M.

Fairly Valued

The company’s latest PE is -3.47, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.50M shares, decreasing 13.97% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 23.49K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.05, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.05

Change



Financials

9.82

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.48

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

9.50

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.25

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.21

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -3.41, which is -22.05% below the recent high of -2.66 and -5.55% above the recent low of -3.60.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 255/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.69, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.78 and the support level at 2.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.69

Change

0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.013

Neutral

RSI(14)

46.882

Neutral

STOCH(KDJ)(9,3,3)

35.717

Sell

ATR(14)

0.198

High Vlolatility

CCI(14)

-8.261

Neutral

Williams %R

48.990

Neutral

TRIX(12,20)

-0.284

Sell

StochRSI(14)

54.138

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.371

Buy

MA10

2.409

Sell

MA20

2.452

Sell

MA50

2.634

Sell

MA100

2.874

Sell

MA200

2.961

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 44.80%, representing a quarter-over-quarter increase of 0.41%. The largest institutional shareholder is The Vanguard, holding a total of 23.49K shares, representing 0.70% of shares outstanding, with 18.80% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Hecht (Peter M)

559.20K

J. Wood Capital Advisors LLC

181.82K

Tyndall Management, LLC

164.78K

American Endowment Foundation

133.03K

Invus Public Equities Advisors, LLC

116.16K

Graul (Regina Margaret)

55.78K

-44.39%

De Souza (Errol B)

50.00K

Geode Capital Management, L.L.C.

31.60K

-0.68%

Higgins (Michael J)

30.74K

+5.67%

The Vanguard Group, Inc.

Star Investors

23.49K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.33. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.